Are atrial fibrillation guidelines altering management? A community based study

Scottish Medical Journal

Volumn 50, Issue 4, 2005, Pages 166-169

  Murdoch, David L ^a   O'Neill, K ^b   Jackson, J ^a   McMahon, A ^c   Rumley, A ^d   Wallace, I ^b   Lowe, G D O ^d   Tait, R C ^d  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^b NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANAMNESIS; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEMOGRAPHY; DRUG CONTRAINDICATION; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; UNITED KINGDOM;

EID: 33644804701     PISSN: 00369330     EISSN: 00369330     Source Type: Journal    
DOI: 10.1177/003693300505000409     Document Type: Article

References (22)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-8.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987;147:1561-4.
3. Cerebral Embolism Task Force. Cardiogenic Brain Embolism: The second report of the Cerebral Embolism Task Force. Arch Neurology 1989;46:727-43.
4. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic treatment in atrial fibrillation: analysis of pooled data from five randomised controlled trials. Arch Intern Med 1994;154:1449-57.
5. Majeed A, Moser K, Carroll K. Trends in the prevalence and management of AF in general practice in England and Wales, 1992-1998: analysis of data from the general practice research database.Heart 2001;86(3):284-8.
6. Connolly SJ.Preventing stroke in atrial fibrillation:why are so many eligible patients not receiving anticoagulant therapy? Can MedAssocJ 1999;161:533-4.
7. Frykman V, Beerman B, Ryden L, Rosenqvist M. Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. European Heart J 2001;22:1954-9.
8. Kalra L, Yu G, Perez I, Lakhani A, Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates to clinical effectiveness. Br Med J2000; 320:1236-9.
9. Taylor FC, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. Br Med J 2001; 322:321-6. (Erratum appears in Br Med J 2001; 322:587).
10. Pengo V, Legnani C, Noventa F, Palareti G on behalf of the ISCOAT Study Group (Italian Study on Complications of Oral Anticoagulant Therapy). Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. Thrombosis and Haemostasis 2001; 85(3): 418-22.
11. Evans A, Kalra L. Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? Arch Int Med 2002; 161(11):1443-7.
12. Scottish Intercollegiate Guidelines Network (SIGN). Antithrombotic therapy. Edinburgh: SIGN 1999. (SIGN publication No. 36)
13. Stewart S, MacIntyre K, MacLeod MMC, Bailey AEM, Capewell S, McMurray JJV. Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986-1996. Eur Heart J (2001);22: 693-701.
14. Sudlow M, Rodgers H, Kenny RA, Thomson R. Population based study of the use of anticoagulants in atrial fibrillation. Br Med J 1997; 314: 1529-30.
15. Lip GY, Golding DJ, Nazir M, Beevers DG, Child DL, Fletcher RI. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Brit J Gen Pract 1997; 57: 285-9.
16. Lip GY, Tean KN, Dunn FG. Treatment of atrial fibrillation in a district general hospital. Brit Heart J 1994; 71: 92-5.
17. Sudlow M, Rodgers H, Kenny RA. Thomson R. Identification of patients with atrial fibrillation in general practice: a study of screening methods. Br Med J 1998, 317:327-328.
18. Devereaux PJ, Anderson DR, Gardner MJ, Putnam W, Flowerdew GJ, Brownell BF, Nagpal S, Cox JL. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. Br Med J 2001; 323: 1218-22.
19. Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation. Arch Int Med 2003; 163(13):1580-1586.
20. Copland M, Walker ID, Tait RC. Oral anticoagulation and haemorrhagic complications in an elderly population with atrial fibrillation. Arch Intern Med 2001; 161:2125-2128.
21. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. New England Journal of Medicine 2003; 349:1019-26.
22. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691-98.